Pursuant to Regulation 30 of SEBI (LODR) Regulations, 2015, please find enclosed the Earnings Presentation for Q2 & H1 FY27.

Ref No.: ZLL/CS/BSE/NSE Date: 04.11.2026 BSE Limited, National Stock Exchange of India Limited Market Operations Dept. Listing Compliance Department P. J. Towers, Dalal Street, Exchange Plaza, Bandra-Kurla Complex, Mumbai- 400 001 Bandra (E), Mumbai – 400 051 Company Code- 541400 (Symbol - ZIMLAB) Dear Sir/Madam, Sub: Earnings Presentation Q2 & H1 FY27 Pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, kindly find enclosed Earnings Presentation Q2 & H1 FY27. Kindly take the intimation on record. Thanking you, Yours faithfully, For ZIM LABORATORIES LIMITED (Piyush Nikhade) Company Secretary and Compliance Officer Membership No. A38972 Encl: As above. ZIM LABORATORIES LIMITED www.zimlab.in I info@zimlab.in I CIN : L99999MH1984PLC032172 Works : B-21/22, MIDC Area, Kalmeshwar – 441 501 Dist. Nagpur Regd. Office : Sadoday Gyan (Ground Floor), Opp. NADT, Nelson Square, Maharashtra, India. Ph. + 91.718.271370 I Fax : +091.7118.271470 Nagpur – 440013. Maharashtra, India. Ph. +091.712.2981960 ZIM LABORATORIES LIMITED Zeal & Innovation in Medicine EARNINGS PRESENTATION Q2 & H1 FY27 Innovation www.zimlab.in Quality People SAFE HARBOUR The presentation has been prepared by ZIM Laboratories Limited ("ZIM" or the "Company") solely for information purposes and does not constitute an offer to sell or recommendation or solicitation of an offer to subscribe for or purchase any securities and nothing contained herein shall form the basis of any contract or commitment whatsoever. By accessing this presentation, you are agreeing to be bound by the trading restrictions. The information contained in this presentation should be considered in the context of the circumstances prevailing at the time and has not been, and will not be, updated to reflect material developments which may occur after the date of the presentation. The information set out herein may be subject to updating, completion, revision, verification and amendment and such information may change materially. This presentation is based on the economic, regulatory, market and other conditions as in effect on the date hereof. It should be understood that subsequent developments may affect the information contained in this presentation, which neither the Company nor its affiliates, advisors or representatives are under an obligation to update, revise or affirm. Certain statements contained in this presentation may be statements of the Company's beliefs, plans and expectations about the future and other forward-looking statements. The forward-looking statements are based on management's current expectations or beliefs as well as a number of assumptions about the Company's operations and facto beyond the Company's control or third-party sources and involve known and unknown risks and uncertainties that could cause actual results to differ materially from those contemplated by the relevant forward- looking statements. Forward looking statements contained in this presentation regarding past trends or activities should not be taken as a representation that such trends or activities will continue in the future. There is no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. You should not place undue reliance on forward looking statements, which speak only as of the date of this presentation. The Company, as such, makes no representation or warranty, express or implied, as to, and does not accept any responsibility or liability with respect to, the fairness, accuracy, completeness or correctness of any information or opinions contained herein. You acknowledge and agree that the Company and/or its affiliated companies and/or their respective employees and/or agents have no responsibility or liability (express or implied) whatsoever and howsoever arising (including, without limitation for any claim, proceedings, action, suits, losses, expenses, damages or costs) which may be brought against or suffered by any person as a result of acting in reliance upon the whole or any part of the contents of this presentation and neither the Company, its affiliated companies nor their respective employees or agents accepts any liability for any error, omission or misstatement, negligent or otherwise, in this presentation and any liability in respect of the presentation or any inaccuracy therein or omission therefrom which might otherwise arise is hereby expressly disclaimed. ZIM Laboratories Limited · For Information Purposes Only · Not an Offer to Buy or Sell Securities Table of Content Q2 & H1 FY27 Highlights Financial performance snapshot for the quarter 02 Financial Performance Q2 & H1 FY27 Revenue, EBITDA, margins and R&D investment trends 03 Business Mix Product and market mix driving the revenue profile 04 R&D & Innovation NIP & OTF pipeline progress, approvals and investment Shareholding Ownership structure and trading volumes - BSE + NSE Q2 FY27 FINANCIAL HIGHLIGHTS Q2 FY27 Vs Q2 FY26 Total Operating Income ₹1,054 Mn ₹887 Mn ▲ 18.9% EBITDA ₹77 Mn ₹78 Mn ▼ -1.2% EBITDA Margin 7.3% 8.8% ▼ 149 bps Total R&D Spend* ₹99 Mn 9.4% of TOI *Incl. ₹45 Mn towards BE studies & regulatory filings BUSINESS & OPERATIONS MOMENTUM Building the base for developed-market entry and operating leverage MARKET ACCESS & CERTIFICATIONS CONTRACTS & PARTNERSHIPS COST RATIONALISATION Australia – TGA GMP certification Operating Income up 24% Old Cephalosporin unit being closed 01 04 07 GMP approval received from the Therapeutic Operating Income up 24% vs H1 F26; Export New Cepha plant commissioned; production Goods Administration, opening the Australian revenue up 24.7% YoY to ₹908 Mn in Q2 FY27, stopped in old plant; all costs being market driven by increase in supplies to RoW accordingly rationalized EU-GMP re-certification on track Contribution % in line with budget Old Unit 3 being closed 02 05 08 CAPA submitted to EU authorities. EBITDA impact on account of increased costs Ancillary unit for manufacturing nutraceutical Inspector’s comments received. Final from upgrading the Co to EU centric business products has been shut down; production response being sent this week; Acceptance readiness on people, products and shifted to new nutraceutical facility; costs on of the CAPA will be subject to satisfactory processes utility and operating exp - being optimized verification Product registrations Building for supply readiness Reduced EU GMP related costs 03 06 09 4 marketing authorisations received in Q2 Pending EU GMP certification, momentum is EU-GMP consultant and CAPA remediation FY27 (1 NIP, 3 OTF); 48 filings across building for supply readiness; traction for new related costs have been mostly incurred; not developed, Pharmerging & RoW markets licensing contracts continue expected to fully recur in H2 Outlook: A leaner cost base, combined with widening developed-market access, positions ZIM for improved operating leverage benefits STATUS UPDATE & PROGRESS ON EU-GMP CAPA REMEDIATION Most of the CAPA remediation plan has been completed and implemented Q2 FY26 01 June / July EU GMP Inspection. Onboarding External Consultant for CAPA Plan. Submission of Q2 FY26 Complete comprehensive CAPA Remediation Plan. Capital Expenditure Orders placed for key systems needed. Contract Manufacturing for alternate site with accreditations finalized for Star Product 1. Q3 FY26 02 Submission of CAPA Progress for up to October 2026. Appointment of European Consultant for CAPA Q3 FY26 Complete Remediation. Strengthening Team in QMS. Training of Team. Additional CMO for specific markets being finalized. Hiring of QA Head. Q4 FY26 Independent assessment by European + Indian Consultant. Effectiveness check on CAPA remediation Q4 FY26 Complete progress . Validation by Consultants . Submission of CAPA Progress.. Initiatives on triggering Audits from other regions. Filing Batches from CMO Partners for Star [Showing first 8,000 characters — download PDF for full document]